Corvus Pharmaceuticals (CRVS) News Today $3.93 -0.01 (-0.25%) Closing price 04:00 PM EasternExtended Trading$4.04 +0.12 (+2.93%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Cantor Fitzgerald Remains a Buy on Corvus Pharmaceuticals (CRVS)June 14, 2025 | theglobeandmail.comCorvus Nicks up on Releasing Preclinical Trial DataJune 11, 2025 | baystreet.ca3 Penny Stocks Wall Street Sees With 243% UpsideJune 11, 2025 | 247wallst.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Bought by Bank of America Corp DEBank of America Corp DE grew its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 23,611.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 96,981 shares of the company's stock after purchasing an additional 96,57June 11, 2025 | marketbeat.comCantor Fitzgerald Forecasts CRVS FY2026 EarningsJune 11, 2025 | americanbankingnews.comCantor Fitzgerald Estimates CRVS FY2026 EarningsCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Corvus Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the company wiJune 10, 2025 | marketbeat.comSquarepoint Ops LLC Increases Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Squarepoint Ops LLC increased its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 712.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 98,144 shares of the company's stock after purchasJune 5, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest UpdateCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 7,230,000 shares, a growth of 25.3% from the April 30th total of 5,770,000 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is presently 7.2 days. Approximately 16.4% of the shares of the stock are sold short.June 4, 2025 | marketbeat.comCorvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisJune 4, 2025 | globenewswire.comCorvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comOMERS ADMINISTRATION Corp Makes New Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)OMERS ADMINISTRATION Corp purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 75,500 shares of the company's stock, valued at approxiMay 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 2,532,718 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Point72 Asset Management L.P. lessened its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 45.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,030,011 shares of the company's stock after selling 2,532,May 20, 2025 | marketbeat.comSphera Funds Management LTD. Acquires New Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Sphera Funds Management LTD. purchased a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 500,491 shares of the company's stock, valued at approximately $2,678,000. Sphera FundsMay 18, 2025 | marketbeat.comRTW Investments LP Invests $14.34 Million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)RTW Investments LP acquired a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,679,479 shares ofMay 18, 2025 | marketbeat.comBridgeway Capital Management LLC Has $221,000 Stock Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Bridgeway Capital Management LLC trimmed its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 67.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,300 shaMay 15, 2025 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Raised to "Hold" at StockNews.comStockNews.com raised Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday.May 15, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC trimmed its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 61.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 129,076 shares of the company's stock after sellinMay 12, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Bought by Barclays PLCBarclays PLC raised its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 10,601,800.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 106,019 shares ofMay 11, 2025 | marketbeat.comCorvus Pharmaceuticals Shares Surge on Study Data Evaluating SoquelitinibMay 10, 2025 | marketwatch.comDeerfield Management Company L.P. Series C Invests $5.35 Million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Deerfield Management Company L.P. Series C acquired a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,000,000 shares of the company'sMay 10, 2025 | marketbeat.comRaymond James Financial Inc. Invests $583,000 in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Raymond James Financial Inc. purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 108,989 shares of the company's stock, valued at approximately $583,000. RaymondMay 10, 2025 | marketbeat.comCorvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expectedMay 9, 2025 | msn.comCorvus Pharmaceuticals shares surge on positive trial resultsMay 9, 2025 | investing.comIs Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | uk.finance.yahoo.comCorvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s PleasedMay 9, 2025 | msn.comCorvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comCorvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisMay 8, 2025 | globenewswire.com74,307 Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Acquired by Acuta Capital Partners LLCAcuta Capital Partners LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 74,307 shares of the company's stock, valued at approximately $398,000. Acuta CaMay 4, 2025 | marketbeat.comForesite Capital Management VI LLC Buys New Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Foresite Capital Management VI LLC bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 1,581,233 shares of the company's stock, valued at approximately $8,460,000. Corvus PharmaceApril 30, 2025 | marketbeat.comCorvus Pharmaceuticals (CRVS) Expected to Announce Earnings on MondayCorvus Pharmaceuticals (NASDAQ:CRVS) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-corvus-pharmaceuticals-inc-stock/)April 30, 2025 | marketbeat.comCorvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025April 23, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Olympus (OtherOCPNF) and Corvus Pharmaceuticals (CRVS)April 23, 2025 | markets.businessinsider.comVivo Capital LLC Has $11.96 Million Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Vivo Capital LLC raised its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 49.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,234,566 shares of the company's stock aApril 23, 2025 | marketbeat.comIs Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires?April 22, 2025 | msn.comCorvus Pharmaceuticals Appoints Richard A. van den Broek to Board of DirectorsApril 9, 2025 | globenewswire.comRaymond James Financial Inc. Makes New Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Raymond James Financial Inc. purchased a new stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 108,989 shares of the company's stock, valued at appApril 8, 2025 | marketbeat.comHC Wainwright Has Optimistic View of CRVS FY2025 EarningsCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Corvus Pharmaceuticals in a report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.March 29, 2025 | marketbeat.comCorvus Pharmaceuticals: Now At Cruising AltitudeMarch 28, 2025 | seekingalpha.comCorvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising TrialsMarch 28, 2025 | seekingalpha.comHC Wainwright Issues Pessimistic Forecast for CRVS EarningsCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at HC Wainwright dropped their FY2028 earnings estimates for Corvus Pharmaceuticals in a research report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now expects that the company will post earnings per sMarch 28, 2025 | marketbeat.comCORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly EarningsMarch 27, 2025 | nasdaq.comCorvus Pharmaceuticals price target raised to $15 from $14 at OppenheimerMarch 27, 2025 | markets.businessinsider.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | insidermonkey.comCorvus Pharmaceuticals (NASDAQ:CRVS) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday.March 27, 2025 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Issues Quarterly Earnings ResultsCorvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.06).March 26, 2025 | marketbeat.comInsider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m ProfitMarch 26, 2025 | finance.yahoo.comCorvus Pharmaceuticals reports Q4 EPS (18c), consensus (12c)March 26, 2025 | markets.businessinsider.comEntryPoint Capital LLC Purchases New Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)EntryPoint Capital LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 116,645 shares of the company's stock,March 26, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | seekingalpha.com Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Media Mentions By Week CRVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼0.700.56▲Average Medical News Sentiment CRVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼22▲CRVS Articles Average Week Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enliven Therapeutics News Aurinia Pharmaceuticals News Niagen Bioscience News Wave Life Sciences News Spyre Therapeutics News CorMedix News Phibro Animal Health News Arcus Biosciences News Collegium Pharmaceutical News AbCellera Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVS) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredTrump Makes Major Crypto AnnouncementTrump's crypto revolution is now fully underway and now, we believe he’s about to deliver on his biggest promi...Crypto 101 Media | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRVS Stock Free CRVS Stock Alerts